Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:21856480rdf:typepubmed:Citationlld:pubmed
pubmed-article:21856480lifeskim:mentionsumls-concept:C0018787lld:lifeskim
pubmed-article:21856480lifeskim:mentionsumls-concept:C0949656lld:lifeskim
pubmed-article:21856480lifeskim:mentionsumls-concept:C1293122lld:lifeskim
pubmed-article:21856480lifeskim:mentionsumls-concept:C0542341lld:lifeskim
pubmed-article:21856480lifeskim:mentionsumls-concept:C0039155lld:lifeskim
pubmed-article:21856480lifeskim:mentionsumls-concept:C2603343lld:lifeskim
pubmed-article:21856480lifeskim:mentionsumls-concept:C1512045lld:lifeskim
pubmed-article:21856480lifeskim:mentionsumls-concept:C2932035lld:lifeskim
pubmed-article:21856480pubmed:issue9792lld:pubmed
pubmed-article:21856480pubmed:dateCreated2011-8-22lld:pubmed
pubmed-article:21856480pubmed:databankReferencehttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:21856480pubmed:abstractTextDecreased systolic function is central to the pathogenesis of heart failure in millions of patients worldwide, but mechanism-related adverse effects restrict existing inotropic treatments. This study tested the hypothesis that omecamtiv mecarbil, a selective cardiac myosin activator, will augment cardiac function in human beings.lld:pubmed
pubmed-article:21856480pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:21856480pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:21856480pubmed:languageenglld:pubmed
pubmed-article:21856480pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:21856480pubmed:citationSubsetAIMlld:pubmed
pubmed-article:21856480pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:21856480pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:21856480pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:21856480pubmed:statusMEDLINElld:pubmed
pubmed-article:21856480pubmed:monthAuglld:pubmed
pubmed-article:21856480pubmed:issn1474-547Xlld:pubmed
pubmed-article:21856480pubmed:authorpubmed-author:SchillerNelso...lld:pubmed
pubmed-article:21856480pubmed:authorpubmed-author:TeerlinkJohn...lld:pubmed
pubmed-article:21856480pubmed:authorpubmed-author:WolffAndrew...lld:pubmed
pubmed-article:21856480pubmed:authorpubmed-author:GoldmanJonath...lld:pubmed
pubmed-article:21856480pubmed:authorpubmed-author:HabibzadehMoh...lld:pubmed
pubmed-article:21856480pubmed:authorpubmed-author:SaikaliKhalil...lld:pubmed
pubmed-article:21856480pubmed:authorpubmed-author:ClarkeCyril...lld:pubmed
pubmed-article:21856480pubmed:authorpubmed-author:MalikFady IFIlld:pubmed
pubmed-article:21856480pubmed:authorpubmed-author:BeeRachelRlld:pubmed
pubmed-article:21856480pubmed:authorpubmed-author:LeeJacqueline...lld:pubmed
pubmed-article:21856480pubmed:authorpubmed-author:ChenMichael...lld:pubmed
pubmed-article:21856480pubmed:authorpubmed-author:EscandonRafae...lld:pubmed
pubmed-article:21856480pubmed:authorpubmed-author:ElliottLyndse...lld:pubmed
pubmed-article:21856480pubmed:copyrightInfoCopyright © 2011 Elsevier Ltd. All rights reserved.lld:pubmed
pubmed-article:21856480pubmed:issnTypeElectroniclld:pubmed
pubmed-article:21856480pubmed:day20lld:pubmed
pubmed-article:21856480pubmed:volume378lld:pubmed
pubmed-article:21856480pubmed:ownerNLMlld:pubmed
pubmed-article:21856480pubmed:authorsCompleteYlld:pubmed
pubmed-article:21856480pubmed:pagination667-75lld:pubmed
pubmed-article:21856480pubmed:meshHeadingpubmed-meshheading:21856480...lld:pubmed
pubmed-article:21856480pubmed:meshHeadingpubmed-meshheading:21856480...lld:pubmed
pubmed-article:21856480pubmed:meshHeadingpubmed-meshheading:21856480...lld:pubmed
pubmed-article:21856480pubmed:meshHeadingpubmed-meshheading:21856480...lld:pubmed
pubmed-article:21856480pubmed:meshHeadingpubmed-meshheading:21856480...lld:pubmed
pubmed-article:21856480pubmed:meshHeadingpubmed-meshheading:21856480...lld:pubmed
pubmed-article:21856480pubmed:meshHeadingpubmed-meshheading:21856480...lld:pubmed
pubmed-article:21856480pubmed:meshHeadingpubmed-meshheading:21856480...lld:pubmed
pubmed-article:21856480pubmed:meshHeadingpubmed-meshheading:21856480...lld:pubmed
pubmed-article:21856480pubmed:meshHeadingpubmed-meshheading:21856480...lld:pubmed
pubmed-article:21856480pubmed:meshHeadingpubmed-meshheading:21856480...lld:pubmed
pubmed-article:21856480pubmed:meshHeadingpubmed-meshheading:21856480...lld:pubmed
pubmed-article:21856480pubmed:meshHeadingpubmed-meshheading:21856480...lld:pubmed
pubmed-article:21856480pubmed:meshHeadingpubmed-meshheading:21856480...lld:pubmed
pubmed-article:21856480pubmed:meshHeadingpubmed-meshheading:21856480...lld:pubmed
pubmed-article:21856480pubmed:meshHeadingpubmed-meshheading:21856480...lld:pubmed
pubmed-article:21856480pubmed:year2011lld:pubmed
pubmed-article:21856480pubmed:articleTitleDose-dependent augmentation of cardiac systolic function with the selective cardiac myosin activator, omecamtiv mecarbil: a first-in-man study.lld:pubmed
pubmed-article:21856480pubmed:affiliationSection of Cardiology, San Francisco Veterans Affairs Medical Center, University of California, San Francisco, CA 94121-1545, USA. john.teerlink@ucsf.edulld:pubmed
pubmed-article:21856480pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:21856480pubmed:publicationTypeRandomized Controlled Triallld:pubmed
pubmed-article:21856480pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:21856480lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:21856480lld:pubmed